What Solid Biosciences Inc. told the SEC could break it.

Solid Biosciences' gene-transfer approach uses capsids derived from a virus, which may be perceived as unsafe or result in unforeseen adverse events; negative public opinion and increased regulatory scrutiny of gene therapy could damage public perception of its safety, reduce physician/patient/payor acceptance, and slow enrollment or approval — and because it plans to run trials (INSPIRE/IMPACT DUCHENNE, ARTEMIS) at sites outside the U.S., FDA acceptance of foreign trial data is conditional, adding development risk.

“Our gene transfer approach utilizes capsids derived from a virus, which may be perceived as unsafe or may result in unforeseen adverse events. Negative public opinion and increased regulatory scrutiny of gene therapy may damage public perception of the safety of gene t”

Solid Biosciences relies on third-party manufacturers for the supply of its gene-therapy candidates SGT-003, SGT-212 and SGT-501 (it announced a partnership with a cell-and-gene-therapy-focused CDMO for SGT-003 manufacture) and plans to rely on third parties for its other candidates; if a manufacturing relationship ends it would need to locate a replacement that may not be readily available or on acceptable terms (causing delay/expense), and it depends on these CDMOs' cGMP compliance, quality systems and capacity — which they also share with other companies — so a CDMO disruption or quality failure could materially delay its programs.

“We currently rely on third-party manufacturers for supply of SGT-003, SGT-212 and SGT-501 and plan to rely on third-party manufacturers for our other Candidates.”

Solid Biosciences has never generated revenue from product sales and does not expect to for the foreseeable future, if ever, while it had an accumulated deficit of $957.8 million at December 31, 2025; it funds its Duchenne and FA gene-therapy programs (SGT-003, SGT-212, SGT-501) through dilutive equity raises (e.g., ~$103.7M in January 2024 and ~$188.0M in February 2025) and depends on continued capital access — so a funding shortfall or inability to raise capital on acceptable terms would force it to delay, scale back or halt development.

“As of December 31, 2025, we had an accumulated deficit of $957.8 million.”

Solid Biosciences depends on FDA (and foreign) approval of novel AAV gene therapies and faces drug-pricing pressure (IRA Medicare provisions and strict foreign price controls in the EU/Canada); it is also exposed to pharmaceutical-tariff policy — after the Supreme Court struck IEEPA tariffs in February 2026, the administration imposed new Section 122 global tariffs of up to 15%, the Commerce Department opened a Section 232 investigation into pharmaceutical/ingredient imports, and a 100% tariff on branded/patented drugs was announced (avoidable by U.S. manufacturing) — any of which could raise the cost of manufacturing its candidates and platform materials and disrupt import/export of raw materials and finished product.

“On February 20, 2026, the U.S. Supreme Court ruled these tariffs unlawful. The Trump Administration immediately imposed new global tariffs pursuant to Section 122 of the Trade Act of 1974, which allows for tariffs of up to 15% for a period of up to 150 days. Separately, in April 2025, the Department of Commerce announced an investigation under Section 232 of the Trade Expansion Act of 1962 into imports of pharmaceuticals and ph”